Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA dodges the bullet

Commentary

Within a few weeks, you'll start hearing a lot of mostly well-intentioned sounds about FDA reform emanating from Washington. But in the end they may signify very little.

As much as it is needed - or perhaps because it is much needed - substantial FDA reform is not likely to happen this year. And next year, all federal legislation will be hostage to presidential politics.

There is, however, some momentum behind congressional efforts to fundamentally change the FDA. The House Commerce Committee's staff, prodded by chairman Thomas J. Bliley, R-Va., the tobacco

Read the full 928 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE